TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15569164

Group type: EXPERIMENTAL
Intervention: Hand-held computers
Number of subjects: 41

Group type: COMPARATOR
Intervention: Paper diaries
Number of subjects: 41
Study: 11180995

Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nonseptic control patients
Number of subjects: 47
Study: 9510365

Group type: COMPARATOR
Intervention: MMC 40 mg (retained in the bladder for 2 hours) once a week for 8 weeks (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EMDA/MMC at a current of 15 mA for 20 minutes once a week for 8 weeks (group B)
Number of subjects: 28
Study: 7844097

Group type: EXPERIMENTAL
Intervention: Classical eye-blink conditioning in persons with autism
Number of subjects: 11

Group type: COMPARATOR
Intervention: Classical eye-blink conditioning in matched controls
Number of subjects: 11
Study: 29714697

Group type: EXPERIMENTAL
Intervention: Bioactive composite resin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Universal hybrid composite resin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer restorative
Number of subjects: 60
Study: 26576838

Group type: EXPERIMENTAL
Intervention: High-FPG group (FPG cut-off of 93 mg/dl for males and 92 mg/dl for females)
Number of subjects: 5039

Group type: COMPARATOR
Intervention: Low-FPG group
Number of subjects: 5039
Study: 24284908

Group type: EXPERIMENTAL
Intervention: Professionally facilitated/psychoeducational online support group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Moderated/peer‐directed online support group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nonactive participants
Number of subjects: 86
Study: 22033466

Group type: EXPERIMENTAL
Intervention: S100A2 promoter-driven conditionally replicative adenovirus (Ad/SA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment with cetuximab or cisplatin plus Ad/SA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab (EGFR-targeting anticancer drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad/SA
Number of subjects: 0
Study: 20436073

Group type: EXPERIMENTAL
Intervention: Low-dose infliximab (IFX) 3 mg/kg at 0, 2, and 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19836989

Group type: EXPERIMENTAL
Intervention: In situ catheter (ISC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Axillary perineural catheter (APC)
Number of subjects: 46
Study: 16953019

Group type: EXPERIMENTAL
Intervention: Prenatal and postpartum lactation support intervention
Number of subjects: 338

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 338
Study: 15247137

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1.2 mg) for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 11401608

Group type: EXPERIMENTAL
Intervention: Achievable benchmark feedback (experimental group; n = 35)
Number of subjects: 2978

Group type: COMPARATOR
Intervention: Multimodal improvement intervention (comparison group; n = 35)
Number of subjects: 2978
Study: 8989339

Group type: EXPERIMENTAL
Intervention: Pre-ICU PRISM score
Number of subjects: 780

Group type: COMPARATOR
Intervention: Predicted mortality rates
Number of subjects: 780
Study: 8424573

Group type: EXPERIMENTAL
Intervention: 30 mg iv ketorolac twice, then 10 mg iv every 30 min as required, followed by 10 mg oral ketorolac every 4-6 h
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 10 mg oral ketorolac
Number of subjects: 221

Group type: COMPARATOR
Intervention: 50 micrograms iv fentanyl
Number of subjects: 221

Group type: COMPARATOR
Intervention: 60 mg codeine plus 600 mg acetaminophen (C+A) orally every 4-6 h
Number of subjects: 221
Study: 3673660

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29499122

Group type: EXPERIMENTAL
Intervention: Increased physical activity for 10 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Reduced daily movement for 10 days
Number of subjects: 2
Study: 27576780

Group type: EXPERIMENTAL
Intervention: Renal denervation plus standardized stepped-care antihypertensive treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standardized stepped-care antihypertensive treatment alone
Number of subjects: 106
Study: 24742407

Group type: EXPERIMENTAL
Intervention: Prophylactic polypropylene mesh at the time of stoma formation
Number of subjects: 42

Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 42
Study: 23188096

Group type: COMPARATOR
Intervention: Hierarchical team structure (Group H)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Non-hierarchical team structure (Group NH)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PGY2 to PGY5
Number of subjects: 49
Study: 20019369

Group type: EXPERIMENTAL
Intervention: IVTA 4 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18502105

Group type: EXPERIMENTAL
Intervention: 42.9 Gy in 13 fractions
Number of subjects: 400

Group type: COMPARATOR
Intervention: 39 Gy in 13 fractions
Number of subjects: 400
Study: 15909489

Group type: EXPERIMENTAL
Intervention: Received contrast group
Number of subjects: 60

Group type: COMPARATOR
Intervention: No contrast group
Number of subjects: 60
Study: 12576945

Group type: EXPERIMENTAL
Intervention: ARM only (n = 19)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ARM + PEEP (n = 20)
Number of subjects: 47

Group type: COMPARATOR
Intervention: PEEP only (n = 8)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ARM (general)
Number of subjects: 47
Study: 10568567

Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (delayed pallidotomy after 6 months)
Number of subjects: 37
Study: 8721124

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 17
Study: 1791932

Group type: EXPERIMENTAL
Intervention: Alcohol 0.3 g/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol 0.6 g/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (both doses)
Number of subjects: 0
Study: 7100264

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trazodone and Amitriptyline
Number of subjects: 30
Study: 30234517

Group type: EXPERIMENTAL
Intervention: IPACK with ACB and modified PAI
Number of subjects: 86

Group type: COMPARATOR
Intervention: PAI
Number of subjects: 86
Study: 29216899

Group type: EXPERIMENTAL
Intervention: Generic-reference comparisons
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Generic-generic comparisons
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Average geometric mean ratio deviation
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Individual ratios for AUCT
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Individual ratios for Cmax
Number of subjects: 700
Study: 25655515

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycle exercise (40 min at 65% peak oxygen uptake)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control subjects (healthy individuals, 14 subjects, 61 ± 5 years old, 12 men and 2 women)
Number of subjects: 14
Study: 24343191

Group type: EXPERIMENTAL
Intervention: Triple P podcasts (7 podcasts over 2 weeks)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 139
Study: 23008442

Group type: EXPERIMENTAL
Intervention: Prompt coronary revascularization
Number of subjects: 381

Group type: COMPARATOR
Intervention: Intensive medical therapy
Number of subjects: 381
Study: 19068041

Group type: EXPERIMENTAL
Intervention: Norwegian version of VEINES-QOL/Sym questionnaire
Number of subjects: 74
Study: 17475963

Group type: EXPERIMENTAL
Intervention: Surgical resection plus radiotherapy (RT), n=31
Number of subjects: 52

Group type: COMPARATOR
Intervention: Radical RT plus chemotherapy (RT), n=21
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 52
Study: 15612617

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg tablets (formulation 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg tablets (formulation 2)
Number of subjects: 0
Study: 11732720

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg single dose (Category I)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 10 days (Category II)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg single dose (Category III)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg per week for 4 weeks (Category IV)
Number of subjects: 180
Study: 9084916

Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg once daily for 10 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily for 10 days
Number of subjects: 12
Study: 7525123

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 18
Study: 3296263

Group type: EXPERIMENTAL
Intervention: Caffeine-free diet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cholesterol-free diet (placebo)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No dietary restrictions (control)
Number of subjects: 56
Study: 31346923

Group type: EXPERIMENTAL
Intervention: Early intervention protocol addressing psychosocial risk factors for delayed return to work.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual (stepped) care arrangements.
Number of subjects: 0
Study: 31283409

Group type: EXPERIMENTAL
Intervention: Neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 164
Study: 27738823

Group type: EXPERIMENTAL
Intervention: Early rehabilitation group (ERG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional care group (CG)
Number of subjects: 40
Study: 24678649

Group type: EXPERIMENTAL
Intervention: Early clamping (EC, within 10 s of delivery)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Late clamping (LC, at 2 min)
Number of subjects: 229
Study: 25129066

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Initiation of spironolactone in patients not on it before admission
Number of subjects: 534
Study: 22275397

Group type: EXPERIMENTAL
Intervention: Certoparin 3000 IU subcutaneously once daily for 6 months
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo subcutaneously once daily for 6 months
Number of subjects: 442
Study: 19706577

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose range of 33 to 67 microg/kg per day
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (untreated SGA subjects)
Number of subjects: 391
Study: 17519435

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 15448286

Group type: EXPERIMENTAL
Intervention: Case management intervention with monthly contact by case managers
Number of subjects: 352
Study: 11843450

Group type: EXPERIMENTAL
Intervention: Carbon fiber-reinforced composite post
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prefabricated stainless steel post
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cast post-and-core
Number of subjects: 30
Study: 9808101

Group type: EXPERIMENTAL
Intervention: Biopsy group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 7715644

Group type: EXPERIMENTAL
Intervention: Special unit care designed to help older persons maintain or achieve independence in self-care activities.
Number of subjects: 651

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Special unit care
Number of subjects: 651
Study: 2620839

Group type: EXPERIMENTAL
Intervention: Reminiscence group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current topics discussion group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 989378

Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no melatonin)
Number of subjects: 0
Study: 31292190

Group type: EXPERIMENTAL
Intervention: Endovascular renal denervation (RDN) using either radiofrequency energy or ultrasound-based approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 28377392

Group type: EXPERIMENTAL
Intervention: RT+TRT (Resistance Training + Testosterone Replacement Therapy)
Number of subjects: 26

Group type: COMPARATOR
Intervention: TRT (Testosterone Replacement Therapy)
Number of subjects: 26
Study: 26964170

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Heat-sensitive acupuncture (group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Force-sensitive acupuncture (group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Force-sensitive moxibustion (group D)
Number of subjects: 80
Study: 24257393

Group type: EXPERIMENTAL
Intervention: IV arginine vasopressin (AVP) 0.07 U/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 30
Study: 21450542

Group type: EXPERIMENTAL
Intervention: Endoscopist-administered propofol sedation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Anaesthetist-administered deep sedation
Number of subjects: 90
Study: 19575117

Group type: EXPERIMENTAL
Intervention: Topical adrenaline 1:2,000
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topical adrenaline 1:10,000
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topical adrenaline 1:50,000
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study: 17708740

Group type: EXPERIMENTAL
Intervention: Tocilizumab (anti-IL-6 receptor monoclonal antibody)
Number of subjects: 0
Study: 15140425

Group type: EXPERIMENTAL
Intervention: Biopharmaceuticals targeting specific disease‐mediating molecules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro and in vivo studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental strategies
Number of subjects: 0
Study: 11396561

Group type: EXPERIMENTAL
Intervention: Emergency Breathing System (EBS) used by 4 to 11 subjects
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Buoyancy of the survival suit
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Total fuselage evacuation time
Number of subjects: 132
Study: 9609610

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 214

Group type: COMPARATOR
Intervention: Ebastine 10 mg
Number of subjects: 214
Study: 8205804

Group type: EXPERIMENTAL
Intervention: Weighted least squares method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cochran‐Mantel‐Haenszel estimator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 0
Study: 1700551

Group type: EXPERIMENTAL
Intervention: High-dose intravenous gammaglobulin administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 791448

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: D-propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Increasing doses of propranolol
Number of subjects: 6
Study: 30658933

Group type: EXPERIMENTAL
Intervention: Self-collected samples
Number of subjects: 7643

Group type: COMPARATOR
Intervention: Clinician-collected samples
Number of subjects: 7643
Study: 28572633

Group type: EXPERIMENTAL
Intervention: Cognitive ability
Number of subjects: 112151

Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 112151

Group type: COMPARATOR
Intervention: Health to cognitive ability
Number of subjects: 112151

Group type: COMPARATOR
Intervention: Educational attainment to physical health
Number of subjects: 112151
Study: 25125508

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard of healthcare (control group)
Number of subjects: 211
Study: 23223507

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (treatment arm)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no intra-arterial thrombolysis)
Number of subjects: 44
Study: 16829095

Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1‐INH) administration (40 IU kg(‐1) during reperfusion and 20 IU kg(‐1) 6 h postoperatively)
Number of subjects: 67

Group type: COMPARATOR
Intervention: CABG+STEMI (without C1‐INH)
Number of subjects: 67

Group type: COMPARATOR
Intervention: CABG‐STEMI (control group)
Number of subjects: 67
Study: 12554151

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10587935

Group type: EXPERIMENTAL
Intervention: Heroin maintenance
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Morphine maintenance
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 1146
Study: 8934109

Group type: EXPERIMENTAL
Intervention: Barium enema examination
Number of subjects: 135
Study: 1675901

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 68
Study: 6871085

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 16
Study: 31372864

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 91

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 91
Study: 31274197

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride 30-mg tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29032916

Group type: COMPARATOR
Intervention: 1 mg kg−1 epidural ropivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg kg−1 ropivacaine and 2 mg kg−1 magnesium sulphate
Number of subjects: 20
Study: 25942606

Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone (OXN)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Oxycodone (OXY)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Morphine (MOR)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Overall adverse events (TEAEs)
Number of subjects: 453
Study: 23369120

Group type: EXPERIMENTAL
Intervention: Self-directed CD-based depression training program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 21803869

Group type: EXPERIMENTAL
Intervention: RUNX1 SNPs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IUS exposure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Murine model with IUS
Number of subjects: 100
Study: 19769482

Group type: EXPERIMENTAL
Intervention: GengNianLe (GNL)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Tibolone (Control)
Number of subjects: 47
Study: 16702931

Group type: EXPERIMENTAL
Intervention: Non-cyanotic congenital heart diseases (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyanotic congenital heart diseases (Group 2)
Number of subjects: 20
Study: 14560344

Group type: COMPARATOR
Intervention: Rate control (Group I)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Rhythm control (Group II)
Number of subjects: 205
Study: 11027389

Group type: EXPERIMENTAL
Intervention: Trephination procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mock trephination procedure (Control)
Number of subjects: 50
Study: 8793433

Group type: EXPERIMENTAL
Intervention: iohexol 300 mgI/ml
Number of subjects: 80

Group type: COMPARATOR
Intervention: ioxaglate 320 mgI/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 80
Study: 1475988

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine administered twice daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 40 mg famotidine administered once daily for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine administered twice daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 40 mg famotidine administered once daily for 8 weeks
Number of subjects: 20
Study: 6486761

Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31394228

Group type: EXPERIMENTAL
Intervention: Ipsilateral antegrade angioplasty
Number of subjects: 53

Group type: COMPARATOR
Intervention: Surgical bypass
Number of subjects: 53
Study: 29925341

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (IVR)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 57
Study: 25559124

Group type: EXPERIMENTAL
Intervention: 3‐h MAT training plus a 12‐month linkage intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3‐h training alone
Number of subjects: 20
Study: 25730933

Group type: EXPERIMENTAL
Intervention: Combination of peloid balneotherapy with magnetic laser therapy and application of efthidermum MPE to the lumbar region
Number of subjects: 78
Study: 23110376

Group type: EXPERIMENTAL
Intervention: 5As communication intervention (Ask, Advise, Agree, Assist, Arrange)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 5As communication intervention
Number of subjects: 375
Study: 20565460

Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 mg transdermal patch every 72 hours for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (transdermal patch every 72 hours for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 mg transdermal patch)
Number of subjects: 30
Study: 17482773

Group type: EXPERIMENTAL
Intervention: 10-item Brief Questionnaire of Smoking Urges (QSU-Brief)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Total Craving Score from QSU-Brief
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Factors 1 and 2 from QSU-Brief
Number of subjects: 626
Study: 16264042

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg two inhalations b.i.d. plus additional inhalations as needed
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/250 microg b.i.d. plus salbutamol as needed
Number of subjects: 2143